Joint Health Tablet Manufacturer for Global Brands

EUPHM operates rotary tablet presses with force feeders and automated weight control. We run single-layer and bi-layer tablets. Standard shapes include round, oval, and caplet. Coating options are film, enteric, and sugar. Our coating pans handle batches from 50 kg to 500 kg. We inspect hardness, friability, and disintegration time in-process. For joint health tablets, common actives are glucosamine sulfate 500-750 mg, chondroitin sulfate 400-600 mg, and MSM 500-1,000 mg. We can combine up to four actives in one tablet.

Packaging lines fill HDPE bottles from 30 to 250 counts. We also run blister packs and sachets. Bottle filling speed reaches 120 bottles per minute. We apply induction seals, child-resistant caps, and tamper-evident bands. Label placement is automatic with 100% vision inspection. For export, we pack in food-grade cartons with desiccant. We ship FOB Shenzhen or Hong Kong. Air freight is available for urgent orders. Full documentation includes certificate of analysis, MSDS, and free sale certificate.

Joint health tablets typically combine glucosamine, chondroitin, MSM, and anti-inflammatory botanicals. We source glucosamine sulfate from shellfish or corn fermentation. Chondroitin comes from bovine or porcine cartilage. MSM is distilled grade. Curcumin can be standardised to 95% curcuminoids with piperine for absorption. Boswellia serrata extract is standardised to 65% boswellic acids. Hyaluronic acid is available at 5-20 mg per tablet. We also offer collagen type II at 10-40 mg. Vitamin C and manganese are common co-factors for cartilage support.

We can adjust excipients to meet clean-label requirements. Binders include microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. We offer vegetarian magnesium stearate and silicon dioxide. For vegan tablets, we use plant-based coatings and no gelatin. We test every batch for heavy metals, microbials, and active potency. Third-party lab testing is available on request. Stability studies follow ICH guidelines at 25°C/60% RH and 40°C/75% RH. We provide 24-month shelf-life data for most formulations.

Our facility is GMP-certified and ISO 22000 registered. We hold HACCP certification and are FDA-registered for dietary supplements. Halal, and vegan certifications are available depending on ingredient sourcing. We maintain full traceability from raw material lot to finished bottle. Each batch has a unique code for recall management. We retain samples for 24 months after production. Our quality team reviews every incoming raw material against a supplier qualification list.

For US, EU, UK, and Middle East buyers, we prepare documentation for customs and regulatory review. This includes certificate of analysis, certificate of origin, and allergen statements. We can provide EU health claims guidance based on EFSA register. For UK, we align with UK Novel Food and nutrition labelling. For Middle East, we follow GSO standards and halal certification. We do not claim FDA approval. Our facility is FDA-registered. We support label review before production to reduce rework. Lead times for documentation are 2-3 working days.

Every joint health tablet batch at EUPHM is tested against a written specification before release. Incoming raw materials are sampled and checked for identity by FTIR or HPLC, and potency for glucosamine sulfate, chondroitin sulfate, MSM and boswellia is confirmed by validated assay. Microbial limits follow USP <61> and <62>, with total aerobic count under 1,000 CFU/g and absence of E. coli and Salmonella. Heavy metals are screened by ICP-MS against EU and US pharmacopoeial limits, and disintegration is tested in purified water at 37°C to confirm the 30-minute requirement for uncoated tablets.

In-process checks run at defined intervals on the tableting line. Weight variation is monitored every 15 minutes with a target RSD below 2.5%, hardness is checked hourly within a 6-12 kp range depending on tablet size, and friability is tested at the start and end of each compression run. Coated tablets are checked for appearance and weight gain after the coating step. Any batch outside specification is placed on hold and investigated before the quality unit signs the certificate of analysis.

The certificate of analysis issued with each batch lists the product name, batch number, manufacturing date, expiry date, tablet weight, active content, microbial results, heavy metals, disintegration time and the specification limits applied. A retention sample of at least twice the quantity needed for full testing is kept for 12 months beyond the declared shelf life. Stability is monitored on the first three commercial batches at 25°C/60% RH and 40°C/75% RH, with testing at 0, 3, 6, 12, 18 and 24 months to support a two-year shelf life claim.

Batch records, raw material certificates, in-process data and finished-product results are retained for five years and are available for buyer review during audits. EUPHM can provide a batch-specific COA in PDF and a summary of the stability protocol before purchase order confirmation. These documents support the technical file that brand owners need for notification in the EU and for retailer quality questionnaires in the US and UK.

Joint health tablets can be packed in HDPE bottles from 60 cc to 500 cc with induction seals and child-resistant or standard caps, in PVC/PVDC blisters of 10 to 30 tablets, or in stick packs and sachets for powder and granule formats. Bottle filling runs at up to 120 bottles per minute, and each bottle is weighed to confirm tablet count before capping. Desiccant can be added where humidity sensitivity is a concern. Cartons are printed to buyer artwork with lot number and expiry date applied by inkjet or laser, and pallets are built to a maximum height of 1.8 m with stretch wrap and edge boards for export.

For the US market, EUPHM applies FDA dietary-supplement label elements to buyer-supplied artwork: statement of identity, net quantity, supplement facts panel with serving size and percent daily value, ingredient list in descending order of weight, and the required address and allergen declarations. For the EU and UK, labels include the nutrition declaration, recommended daily portion, and the mandatory 'do not exceed stated dose' and 'food supplements should not replace a balanced diet' statements. EUPHM does not provide regulatory sign-off but checks artwork against a label checklist before printing.

Lot and expiry coding is applied to each primary unit, carton and shipper. The coding format follows the buyer's specification, and EUPHM retains a printed sample of each coding run for traceability. Amazon sellers can receive FNSKU labels applied to each unit and poly-bagged units where required, with carton labels showing FBA shipment ID and box quantity. Retail-ready display cartons and shelf-ready trays can be produced on request, subject to a minimum run of 1,000 units per SKU.

Packaging materials are checked against the buyer's approved specification before use. Bottles and caps are inspected for defects, and printed cartons are compared to the approved artwork proof. EUPHM can ship packaging components to the buyer for approval before mass production, and retains a packaging specification sheet for each SKU. Where the buyer supplies artwork, a pre-press proof is issued for written approval, and no printing proceeds without that approval.

The sample process for a joint health tablet starts with a formulation brief and target tablet weight. EUPHM provides a quotation within three working days and produces a sample batch of 100 to 500 tablets in 7-10 working days after the brief is confirmed. Sample cost is quoted per project and is credited against the first mass-production order above 1,000 units. Buyers receive the sample with a draft COA and a packaging mock-up for review before approving mass production.

Mass production begins after written sample approval and receipt of the deposit. The production window is 20-35 working days for standard formulations and packaging, and up to 45 working days where new tooling, special packaging or third-party testing is required. The MOQ is 1,000 units per SKU. Line capacity is up to 2 million tablets per day, so larger orders are scheduled across multiple shifts rather than extended beyond the stated window.

Delivery is quoted under EXW, FOB Shenzhen or Hong Kong, or DDP to the buyer's warehouse. Air freight takes 5-10 days door to door and is typically used for samples and launch quantities under 500 kg. Sea freight takes 25-40 days depending on destination port and is cost-effective above 500 kg. EUPHM provides a commercial invoice, packing list, bill of lading or air waybill, certificate of analysis, material safety data sheet where applicable, and a free-sale certificate on request. Phytosanitary certificates are issued only where the destination requires them for plant-derived ingredients.

Buyers are responsible for import registration and market notification in the destination country. EUPHM can share the technical documents needed for those filings, including the COA, specification sheet, stability summary and label artwork. For repeat orders, the production window can be shortened to 15-20 working days where raw materials are held in stock and artwork is unchanged. Shipping schedules are confirmed at order acknowledgement, and EUPHM provides a production status update at the start of tableting and at packaging.